Sutro Biopharma to Participate in Three Upcoming Investor Conferences

Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO), a clinical-stage drug development company, announced CEO Bill Newell will present at three virtual investor conferences in November 2021. The presentations include:

• Credit Suisse 30th Annual Healthcare Conference: Nov. 10, 2021, 4:20 p.m. EST
• Stifel Virtual Healthcare Conference: Nov. 15, 2021, 1:20 p.m. EST
• Jefferies London Healthcare Conference: Nov. 18, 2021, 3:00 a.m. EST

Live webcasts can be accessed via the company's website.

SOUTH SAN FRANCISCO, Calif., Nov. 2, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Chief Executive Officer, Bill Newell, will participate in three upcoming virtual investor conferences.

Presentation Details
Credit Suisse 30^th Annual Healthcare Conference
Format: Virtual Presentation
Date: Wednesday, Nov. 10, 2021
Time: 4:20 p.m. EST / 1:20 p.m. PST

Stifel Virtual Healthcare Conference
Format: Virtual Presentation
Date: Monday, Nov. 15, 2021
Time: 1:20 p.m. EST / 10:20 a.m. PST

Jefferies London Healthcare Conference
Format: Pre-recorded Fireside Chat
Date: Thursday, Nov. 18, 2021
Time: 3:00 a.m. EST / 12:00 a.m. PST / 8:00 a.m. GMT

Live webcasts of each presentation can be accessed through the Events and Presentations page of the Investor Relations section on the company's website at www.sutrobio.com. Archived replays of the webcasts will be available on the company's website for approximately 30 days following each live presentation.

About Sutro Biopharma 
Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development, and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.

Sutro's proprietary and integrated cell-free protein synthesis platform XpressCF® and site-specific conjugation platform XpressCF+™ led to the discovery of STRO-001 and STRO-002, Sutro's first two internally-developed ADCs. STRO-001 is a CD74-targeting ADC currently under investigation in a Phase 1 clinical trial for patients with advanced B-cell malignancies, and was granted Orphan Drug Designation by the FDA for multiple myeloma. STRO-002, a folate receptor alpha (FolRα)-targeting ADC, is currently being investigated in a Phase 1 clinical trial for patients with ovarian and endometrial cancers and was granted Fast Track designation by the FDA for ovarian cancer. A third product candidate, CC-99712, a BCMA-targeting ADC, which is part of Sutro's collaboration with Bristol Myers Squibb, formerly Celgene Corporation, is enrolling patients for its Phase 1 clinical trial of patients with multiple myeloma and has received Orphan Drug Designation from the FDA. A fourth product candidate, M1231, a MUC1-EGFR, first-in-class bispecific ADC, which is part of Sutro's collaboration with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono), is enrolling patients for its Phase 1 clinical trial of patients with metastatic solid tumors, non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma. These four product candidates above being evaluated in clinical trials resulted from Sutro's XpressCF® and XpressCF+™ technology platforms. Bristol Myers Squibb and EMD Serono have worldwide development and commercialization rights for CC-99712 and M1231, respectively, for which Sutro is entitled to milestone or contingent payments and tiered royalties.

Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need. To date, Sutro's platform has led to ADCs, bispecific antibodies, cytokine-based immuno-oncology therapies, and vaccines directed at precedented targets in clinical indications where the current standard of care is suboptimal.

The platform allows it to accelerate discovery and development of potential first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates. In addition to developing its own oncology pipeline, Sutro is collaborating with select pharmaceutical and biotech companies to discover and develop novel, next-generation therapeutics.

Follow Sutro on Twitter, @Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.

Investor Contacts 
Annie J. Chang 
Sutro Biopharma 
(650) 801-5728 
ajchang@sutrobio.com 

Media Contacts 
Maggie Beller 
Russo Partners 
(646) 942-5631 
Maggie.beller@russopartnersllc.com 

 

View original content:https://www.prnewswire.com/news-releases/sutro-biopharma-to-participate-in-three-upcoming-investor-conferences-301413773.html

SOURCE Sutro Biopharma

FAQ

What is the purpose of Sutro Biopharma's participation in the November 2021 investor conferences?

Sutro Biopharma's CEO, Bill Newell, will discuss the company's advancements in cancer therapeutics at three virtual investor conferences.

When will Sutro Biopharma present at the Credit Suisse 30th Annual Healthcare Conference?

Sutro Biopharma will present at the Credit Suisse 30th Annual Healthcare Conference on November 10, 2021, at 4:20 p.m. EST.

What is the schedule for Sutro Biopharma's investor conference presentations in November 2021?

Sutro Biopharma's presentations are scheduled for November 10, 15, and 18, 2021.

How can investors access the presentations given by Sutro Biopharma?

Investors can access the live webcasts of Sutro Biopharma's presentations through the Events and Presentations page on their website.

What are the key product candidates being developed by Sutro Biopharma?

Sutro Biopharma is developing STRO-001, STRO-002, CC-99712, and M1231, targeted at various cancers.